Merck claims hepatitis C patent win
STILLFX / Shutterstock.com
Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck, Gilead, patent, damages, Sovaldi, Harvoni, sofosbuvir, US District Court for the Northern District of California